and Supplementary Table 18). We observed the largest improvement for RA from R2 = 1.4% (s.d. = 0.33%) in the standard PRS to R2 = 4.1% (s.d. = 0.53%, one-tailed difference of means P < 9.8 × 10−6) in the functionally informed PRS using the B cell TBP IMPACT annotation. For asthma, R2 = 0.37% (s.d. = 0.10%) in the standard PRS versus R2 = 0.75% (s.d. = 0.14%, P < 0.013) in the functionally informed PRS. For MCV, R2 = 3.0% (s.d. = 0.10%) in the standard PRS versus R2 = 4.1% (s.d. = 0.12%, P < 1.2 × 10−13) in the functionally informed PRS. For PrCa, R2 = 4.5% (s.d. = 0.36%) in the standard PRS versus R2 = 6.4% (s.d. = 0.45%, P< 6.1 × 10−4) in the functionally informed PRS. For height, R2 = 4.2% (s.d. = 0.10%) in the standard PRS versus R2 = 5.6% (s.d. = 0.12%, P < 8.7 × 10−20) in the functionally informed PRS.
